Schechter Investment Advisors LLC Invests $244,000 in Humana Inc. (NYSE:HUM)

Schechter Investment Advisors LLC bought a new stake in Humana Inc. (NYSE:HUM - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 963 shares of the insurance provider's stock, valued at approximately $244,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. State Street Corp raised its position in Humana by 1.0% in the 3rd quarter. State Street Corp now owns 5,357,420 shares of the insurance provider's stock worth $1,701,582,000 after purchasing an additional 53,272 shares during the period. FMR LLC lifted its stake in shares of Humana by 23.4% in the 3rd quarter. FMR LLC now owns 3,388,859 shares of the insurance provider's stock valued at $1,073,387,000 after acquiring an additional 643,291 shares during the last quarter. Pzena Investment Management LLC boosted its holdings in Humana by 8.1% during the 3rd quarter. Pzena Investment Management LLC now owns 2,506,250 shares of the insurance provider's stock valued at $793,830,000 after acquiring an additional 187,903 shares during the period. Ontario Teachers Pension Plan Board boosted its holdings in Humana by 6.5% during the 3rd quarter. Ontario Teachers Pension Plan Board now owns 1,173,535 shares of the insurance provider's stock valued at $371,705,000 after acquiring an additional 71,910 shares during the period. Finally, Sanders Capital LLC grew its position in Humana by 1.0% during the 3rd quarter. Sanders Capital LLC now owns 1,168,341 shares of the insurance provider's stock worth $370,060,000 after acquiring an additional 11,923 shares during the last quarter. Hedge funds and other institutional investors own 92.38% of the company's stock.

Remove Ads

Humana Stock Down 3.2 %

Shares of NYSE:HUM traded down $8.35 on Monday, hitting $251.41. 2,108,404 shares of the company traded hands, compared to its average volume of 1,683,051. The stock has a 50 day simple moving average of $271.80 and a 200-day simple moving average of $283.10. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.68. The company has a market cap of $30.33 billion, a PE ratio of 25.27, a PEG ratio of 2.05 and a beta of 0.57. Humana Inc. has a 52 week low of $213.31 and a 52 week high of $406.46.

Humana (NYSE:HUM - Get Free Report) last announced its quarterly earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share for the quarter, beating the consensus estimate of ($2.26) by $0.10. Humana had a net margin of 1.02% and a return on equity of 11.70%. As a group, research analysts expect that Humana Inc. will post 16.47 earnings per share for the current year.

Humana Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, April 25th. Investors of record on Friday, March 28th will be issued a $0.885 dividend. The ex-dividend date of this dividend is Friday, March 28th. This represents a $3.54 annualized dividend and a yield of 1.41%. Humana's payout ratio is 35.58%.

Insiders Place Their Bets

In other Humana news, insider Timothy S. Huval sold 3,703 shares of the business's stock in a transaction on Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total transaction of $948,930.78. Following the completion of the sale, the insider now directly owns 8,181 shares in the company, valued at approximately $2,096,463.06. The trade was a 31.16 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.32% of the stock is owned by insiders.

Wall Street Analyst Weigh In

HUM has been the subject of a number of analyst reports. JPMorgan Chase & Co. dropped their price objective on Humana from $257.00 to $256.00 and set a "neutral" rating for the company in a research note on Tuesday, February 18th. StockNews.com lowered shares of Humana from a "buy" rating to a "hold" rating in a report on Wednesday, March 5th. Cantor Fitzgerald reaffirmed a "neutral" rating and set a $290.00 price objective on shares of Humana in a research note on Wednesday, February 12th. Piper Sandler raised their target price on Humana from $270.00 to $288.00 and gave the stock a "neutral" rating in a research note on Wednesday, January 15th. Finally, Truist Financial upped their price target on Humana from $260.00 to $290.00 and gave the company a "hold" rating in a research report on Monday, January 6th. Twenty research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, Humana presently has an average rating of "Hold" and an average price target of $285.68.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.